Matyas GR, Beck Z, Karasavvas N, Alving CR. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta. 2009 Mar;1788(3):660-5. Epub 2008 Dec 3.
Kijak GH, Walsh AM, Koehler RN, Moqueet N, Eller LA, Eller M, Currier JR, Wang Z, Wabwire-Mangen F, Kibuuka HN, Michael NL, Robb ML, McCutchan FE. HLA class I allele and haplotype diversity in Ugandans supports the presence of a major east African genetic cluster. Tissue Antigens. 2009 Mar;73(3):262-9.
Kulkarni SS, Lapedes A, Tang H, Gnanakaran S, Daniels MG, Zhang M, Bhattacharya T, Li M, Polonis VR, McCutchan FE, Morris L, Ellenberger D, Butera ST, Bollinger RC, Korber BT, Paranjape RS, Montefiori DC. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology. 2009 Mar 15;385(2):505-20. Epub 2009 Jan 23.
Steers NJ, Peachman KK, McClain SR, Alving CR, Rao M. Human immunodeficiency virus type 1 Gag p24 alters the composition of immunoproteasomes and affectsantigen presentation. J Virol. 2009 Jul;83(14):7049-61. Epub 2009 Apr 29.
Koehler RN, Walsh AM, Moqueet N, Currier JR, Eller MA, Eller LA, Wabwire-Mangen F, Michael NL, Robb ML, McCutchan FE, Kijak GH. High-throughput genotyping of KIR2DL2/L3, KIR3DL1/S1, and their HLA class I ligands using real-time PCR. Tissue Antigens. 2009 Jul;74(1):73-80.
Eller MA, Eller LA, Ouma BJ, Thelian D, Gonzalez VD, Guwatudde D, McCutchan FE, Marovich MA, Michael NL, de Souza MS, Wabwire-Mangen F, Robb ML, Currier JR, Sandberg JK. Elevated Natural Killer Cell Activity Despite Altered Functional and Phenotypic Profile in Ugandans With HIV-1 Clade A or Clade D Infection. J Acquir Immune Defic Syndr. 2009 Aug;51(4):380-389.
Gandhi RT, O'Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J, Baglyos L, Adams E, Fox L, Purdue L, Marshak A, Flynn T, Masih R, Schock B, Mildvan D, Schlesinger SJ, Marovich MA, Bhardwaj N, Jacobson JM; for the AIDS Clinical Trials Group A5130 team. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine. 2009 Oct;27(43):6088-94.
Sun P, Fernandez S, Marovich MA, Palmer DR, Celluzzi CM, Boonnak K, Liang Z, Subramanian H, Porter KR, Sun W, Burgess TH. Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus. Virology. 2009 Jan 20; 383(2):207-15. Epub 2008 Nov 17.
Walley NM, Julg B, Dickson SP, Fellay J, Ge D, Walker BD, Carrington M, Cohen MS, de Bakker PI, Goldstein DB, Shianna KV, Haynes BF, Letvin NL, McMichael AJ, Michael NL, Weintrob AC. The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. Cell Host Microbe. 2009 May 8;5(5):408-10; author reply 418-9.
Matyas GR, Wieczorek L, Beck Z, Ochsenbauer-Jambor C, Kappes JC, Michael NL, Polonis VR, Alving CR. Neutralizing antibodies induced by liposomal HIV-1glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS. 2009 Oct 23;23(16):2069-77.
Steers NJ, Peachman KK, McClain S, Alving CR, Rao M. Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines. Vaccine. 2009 Nov 16;27(49):6939-49.
Geldmacher C, Metzler IS, Tovanabutra S, Asher TE, Gostick E, Ambrozak DR, Petrovas C, Schuetz A, Ngwenyama N, Kijak G, Maboko L, Hoelscher M, McCutchan F, Price DA, Douek DC, Koup RA. Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response. Blood. 2009 Aug 20;114(8):1553-62.
Qin Lia, Kristina K. Peachman, Laurie Sower, Stephen H. Lepplad, Sathish B. Shivachandra, Gary R. Matyas, Johnny W. Peterson, Carl R. Alving, Mangala Rao and Venigalla B. Rao, Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits. Open Vaccine J. 2009;2:92-99.
Polonis VR, Schuitemaker H, Bunnik EM, Brown BK, Scarlatti G. Impact of host cell variation on the neutralization of HIV-1 in vitro. Curr Opin HIV AIDS. 2009 Sep;4(5):400-7.
Nedellec R, Coetzer M, Shimizu N, Hoshino H, Polonis VR, Morris L, Mårtensson UE, Binley J, Overbaugh J, Mosier DE. Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype. J Virol. 2009 Sep;83(17):8353-63. Epub 2009 Jun 24.
Shaffer DN, Ngetich IK, Bautista CT, Sawe FK, Renzullo PO, Scott PT, Kibaya RM, Imbuki KO, Michael NL, Birx DL, Wasunna MK, Robb ML. HIV-1 Incidence Rates and Risk Factors in Agricultural Workers and Dependents in Rural Kenya: 36-Month Follow-Up of the Kericho HIV Cohort Study. J Acquir Immune Defic Syndr. 2009 Oct [Epub ahead of print]
Earl PL, Cotter C, Moss B, VanCott T, Currier J, Eller LA, McCutchan F, Birx DL, Michael NL, Marovich MA, Robb M, Cox JH. Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine. 2009 Sep 25;27(42):5885-95. Epub 2009 Aug 3.
Phillips CJ, Matyas GR, Hansen CJ, Alving CR, Smith TC, Ryan MA. Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. Vaccine. 2009 Jun 12;27(29):3921-6. Epub 2009 May 3.
Kibuuka H, Guwatudde D, Kimutai R, Maganga L, Maboko L, Watyema C, Sawe F, Shaffer D, Matsiko D, Millard M, Michael N, Wabwire-Mangen F, Robb M. Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I/II trial in East Africa. PLoS ONE. 2009;4(4):e5164. Epub 2009 Apr 10.
Eller MA, Eller LA, Ouma BJ, Thelian D, Gonzalez VD, Guwatudde D, McCutchan FE, Marovich MA, Michael NL, de Souza MS, Wabwire-Mangen F, Robb ML, Currier JR, Sandberg JK. Elevated natural killer cell activity despite altered functional and phenotypic profile in Ugandans with HIV-1 clade A or clade D infection. J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):380-9.
Earl PL, Cotter C, Moss B, VanCott T, Currier J, Eller LA, McCutchan F, Birx DL, Michael NL, Marovich MA, Robb M, Cox JH. Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine. 2009 Sep 25;27(42):5885-95. Epub 2009 Aug 3.
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Eng J Med. 2009 Dec 3;361(23):2209-20. Epub 2009 Oct 20.
Gandhi RT, O'Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J, Baglyos L, Adams E, Fox L, Purdue L, Marshak A, Flynn T, Masih R, Schock B, Mildvan D, Schlesinger SJ, Marovich MA, Bhardwaj N, Jacobson JM; AIDS Clinical Trials Group A5130 team. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1 infected patients on antiretroviral therapy. Vaccine. 2009 Oct 9;27(43):6088-94. Epub 2009 May 29.
Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine. 2009 Jul 16;27(33):4468-74. Epub 2009 May 29.
Guwatudde D, Wabwire-Mangen F, Eller LA, Eller M, McCutchan F, Kibuuka H, Millard M, Sewankambo N, Serwadda D, Michael N, Robb M; Kayunga Cohort Research Team. Relatively low HIV infection rates in rural Uganda, but with high potential for a rise: a cohort study in Kayunga District, Uganda. PLoS ONE. 2009;4(1):e4145. Epub 2009 Jan 7.
Kigozi G, Lukabwe I, Kagaayi J, Wawer MJ, Nantume B, Kigozi G, Nalugoda F, Kiwanuka N, Wabwire-Mangen F, Serwadda D, Ridzon R, Buwembo D, Nabukenya D, Watya S, Lutalo T, Nkale J, Gray RH. Sexual satisfaction of women partners of circumcised men in a randomized trial of male circumcision in Rakai, Uganda. BJU Int. 2009 Jun 12. [Epub ahead of print]
Tovanabutra S, Kijak GH, Beyrer C, Gammon-Richardson C, Sakkhachornphop S, Vongchak T, Jittiwutikarn J, Razak MH, Sanders-Buell E, Robb ML, Suriyanon V, Birx DL, Michael NL, Celentano DD, McCutchan FE. Identification of CRF34_01B, a second circulating recombinant form unrelated to and more complex than CRF15_01B, among injecting drug users in northern Thailand. AIDS Res Hum Retroviruses. 2007 Jun; 23(6):829-33.
Bautista CT, Singer DE, O'Connell RJ, Crum-Cianflone N, Agan BK, Malia JA, Sanchez JL, Peel SA, Michael NL, Scott PT. Herpes simplex virus type 2 and HIV infection among US military personnel: implications for health prevention programmes. Int J STD AIDS. 2009 Sep; 20(9):634-7.
Arroyo MA, Sateren WB, Foglia G, Kibaya R, Langat L, Wasunna M, Bautista CT, Scott PT, Shaffer DN, Robb ML, Michael NL, Birx DL, McCutchan FE. Short communication: HIV type 1 genetic diversity among tea plantation workers in Kericho, Kenya. AIDS Res Hum Retrovirus. 2009 Nov; 25(11):1061-4.
Urban TJ, Weintrob AC, Fellay J, Colombo S, Shianna KV, Gumbs C, Rotger M, Pelak K, Dang KK, Detels R, Martinson JJ, O'Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Telenti A, Michael NL, Goldstein DB. CCL3L1 and HIV/AIDS susceptibility. Nat Med. 2009 Oct;15(10):1110-2.
Ngauy V, Bautista CT, Duffy K, Humphries MJ, Lewis Y, Marovich M. Increased African-American involvement in vaccine studies. J Clin Epidemiol. 2009 Jan; 62(1):111-3.
Kiwanuka N, Laeyendecker O, Quinn TC, Wawer MJ, Shepherd J, Robb M, Kigozi G, Kagaayi J, Serwadda D, Makumbi FE, Reynolds SJ, Gray RH. HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda. AIDS. 2009 Nov 27;23(18):2479-84.